Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Intravenous tenecteplase (TNK) efficacy has not been well demonstrated in acute ischemic stroke (AIS) beyond 4.5 hours after onset. This study aimed to determine the effect of intravenous TNK for AIS within 4.5 to 24 hours of onset. Methods In this pilot trial, eligible AIS patients with diffusion-weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch were randomly allocated to intravenous TNK (0.25 mg/kg) or standard care within 4.5–24 hours of onset. The primary endpoint was excellent functional outcome at 90 days (modified Rankin Scale [mRS] score of 0–1). The primary safety endpoint was symptomatic intracranial hemorrhage (sICH). Results Of the randomly assigned 80 patients, the primary endpoint occurred in 52.5% (21/40) of TNK group and 50.0% (20/40) of control group, with no significant difference (unadjusted odds ratio, 1.11; 95% confidence interval 0.46–2.66; <i>P</i>=0.82). More early neurological improvement occurred in TNK group than in control group (11 vs. 3, <i>P</i>=0.03), but no significant differences were found in other secondary endpoints, such as mRS 0–2 at 90 days, shift analysis of mRS at 90 days, and change in National Institutes of Health Stroke Scale score at 24 hours and 7 days. There were no cases of sICH in this trial; however, asymptomatic intracranial hemorrhage occurred in 3 of the 40 patients (7.5%) in the TNK group. Conclusion This phase 2, randomized, multicenter study suggests that intravenous TNK within 4.5–24 hours of onset may be safe and feasible in AIS patients with a DWI-FLAIR mismatch.
Abstract
Background and Purpose Intravenous tenecteplase (TNK) efficacy has not been well demonstrated in acute ischemic stroke (AIS) beyond 4.5 hours after onset. This study aimed to determine the effect of intravenous TNK for AIS within 4.5 to 24 hours of onset. Methods In this pilot trial, eligible AIS patients with diffusion-weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch were randomly allocated to intravenous TNK (0.25 mg/kg) or standard care within 4.5–24 hours of onset. The primary endpoint was excellent functional outcome at 90 days (modified Rankin Scale [mRS] score of 0–1). The primary safety endpoint was symptomatic intracranial hemorrhage (sICH). Results Of the randomly assigned 80 patients, the primary endpoint occurred in 52.5% (21/40) of TNK group and 50.0% (20/40) of control group, with no significant difference (unadjusted odds ratio, 1.11; 95% confidence interval 0.46–2.66; <i>P</i>=0.82). More early neurological improvement occurred in TNK group than in control group (11 vs. 3, <i>P</i>=0.03), but no significant differences were found in other secondary endpoints, such as mRS 0–2 at 90 days, shift analysis of mRS at 90 days, and change in National Institutes of Health Stroke Scale score at 24 hours and 7 days. There were no cases of sICH in this trial; however, asymptomatic intracranial hemorrhage occurred in 3 of the 40 patients (7.5%) in the TNK group. Conclusion This phase 2, randomized, multicenter study suggests that intravenous TNK within 4.5–24 hours of onset may be safe and feasible in AIS patients with a DWI-FLAIR mismatch.
참고문헌 (25)
- Powers WJ, "Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2019, pp.50, e344~e418
- Berge E, "European Stroke Organisation(ESO)guidelines on intravenous thrombolysis for acute ischaemic stroke", Eur Stroke J, 6, pp.I~LXII (2021)
- Logallo N, "Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial", Lancet Neurol, 16, pp.781~788 (2017)
- Menon BK, "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial", Lancet, 400, pp.161~169 (2022)
- Wang Y, "Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial", Lancet, 401, pp.645~654 (2023)
- Campbell BCV, "Tenecteplase versus alteplase before thrombectomy for ischemic stroke", N Engl J Med, 378, pp.1573~1582 (2018)
- Bivard A, "Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial", Lancet Neurol, 21, pp.520~527 (2022)
- Ma H, "Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke", N Engl J Med, 380, pp.1795~1803 (2019)
- Thomalla G, "MRI-guided thrombolysis for stroke with unknown time of onset", N Engl J Med, 379, pp.611~622 (2018)
- Mahesh Kate, "Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom Onset", 대한뇌졸중영문학회지, 20(1), pp.122~130 (2018), 대한뇌졸중학회[DOI]
- Coutts SB, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion", Stroke, 46, pp.769~774 (2015)
- Liu L, "Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders : executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases", Stroke Vasc Neurol, 5, pp.159~176 (2020)
- Chinese Society of Neurology, "Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018", Chin J Neurol, 51, pp.666~682 (2018)
- Kharitonova T, "Association of early National Institutes of Health Stroke Scale improvement with vessel recanalization and functional outcome after intravenous thrombolysis in ischemic stroke", Stroke, 42, pp.1638~1643 (2011)
- Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
- Katsanos AH, "Off-label use of tenecteplase for the treatment of acute ischemic stroke : a systematic review and meta-analysis", JAMA Netw Open, 5, pp.e224506~ (2022)
- Mahawish K, "Switching to tenecteplase for stroke thrombolysis : real-world experience and outcomes in a regional stroke network", Stroke, 52, pp.e590~e593 (2021)
- Tsivgoulis G, "Intravenous thrombolysis with tenecteplase for the treatment of acute ischemic stroke", Ann Neurol, 92, pp.349~357 (2022)
- Ma P, "Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis", J Neurol, 269, pp.5262~5271 (2022)
- Thomalla G, "Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging : systematic review and meta-analysis of individual patient data", Lancet, 396, pp.1574~1584 (2020)
- Thomalla G, "DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset(PREFLAIR) : a multicentre observational study", Lancet Neurol, 10, pp.978~986 (2011)
- Koga M, "Thrombolysis with alteplase at 0.6 mg", kg for stroke with unknown time of onset: a randomized controlled trial, 2020, pp.51, 1530~1538
- Albers GW, "A phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): rationale and design", Int J Stroke, 18, pp.237~241 (2023)
- Roaldsen MB, "Tenecteplase in wake-up ischemic stroke trial : protocol for a randomized-controlled trial", Int J Stroke, 16, pp.990~994 (2021)
- Campbell BCV, "Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging : a systematic review and meta-analysis of individual patient data", Lancet, 394, pp.139~147 (2019)